PMID- 26242125 OWN - NLM STAT- MEDLINE DCOM- 20160426 LR - 20181202 IS - 1003-5370 (Print) IS - 1003-5370 (Linking) VI - 35 IP - 6 DP - 2015 Jun TI - [Effect of Guanmaitong Tablet on ERK and p38 Protein of TLR2 Pathway Expression in Cerebral Ischemia/Reperfusion Rats: an Experimental Study]. PG - 712-6 AB - OBJECTIVE: To explore the inflammatory cascade mechanism through Toll like receptor 2 (TLR2) pathway after cerebral ischemia/reperfusion, and to study molecular mechanisms of Guanmaitong (GMT) Tablet for protecting brain damage. METHODS: We used bolt-line method to block/release the middle cerebral artery, causing cerebral ischemia/reperfusion (I/R) injury model. GMT Tablet was given by gastrogavage. Rats were then divided into the high dose GMT group (1200 mg/kg), the middle dose GMT group (600 mg/kg), the low dose GMT group (300 mg/kg), the positive control group (Tanakan, 20 mg/kg). Their right brain tissues were fixed in 10% neutral formalin. TLR2 expressions were detected by immunofluorescence staining. The total protein was extracted from right brain tissues by ultrasonica- tion. Expression levels of extracellular regulated protein kinases (ERK), phospho-extracellular regulated protein kinases (p-ERK), p38-mitogen activated protein kinases (p-ERK), phospho-p38-mitogen activated protein kinases [p-p38-MAPKs(p-p38)] were assessed by Western blot. Abdominal aortic blood was withdrawn. IL-6 and IL-1beta levels were detected by ELISA in brain tissues and serum. RESULTS: Compared with the sham-oepration group, expression levels of TLR2, ERK, p-ERK, p38, p-p38 protein were up-regulated (P < 0.05, P < 0.01), and contents of IL-6 and IL-1beta in brain tissues and serum were increased in the model group (P < 0.01). Expression levels of TLR2, ERK, p-ERK, p38, p-p38 were down-regulated (P < 0.05, P < 0.01), and contents of IL-6 and IL-1beta were reduced in brain tissues and serum in middle and high dose GMT groups (P < 0.05, P < 0.01). CONCLUSIONS: TLR2 pathway was involved in cerebral I/R injury. GMT protected neurons by down-regulating protein expressions of TLR2, ERK, p-ERK, p38, p-p38 and contents of IL-1beta and IL-6. FAU - Zhang, Cui-xiang AU - Zhang CX FAU - Liu, Jian-xun AU - Liu JX FAU - Li, Dan AU - Li D FAU - Li, Lei AU - Li L FAU - Fu, Jian-hua AU - Fu JH FAU - Hou, Jin-cai AU - Hou JC FAU - Du, Xue-mei AU - Du XM FAU - Zhang, Fa-chang AU - Zhang FC LA - chi PT - Journal Article PL - China TA - Zhongguo Zhong Xi Yi Jie He Za Zhi JT - Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine JID - 9211576 RN - 0 (Drugs, Chinese Herbal) RN - 0 (Interleukin-1beta) RN - 0 (Interleukin-6) RN - 0 (Tablets) RN - 0 (Toll-Like Receptor 2) RN - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases) SB - IM MH - Animals MH - Blotting, Western MH - Brain Ischemia/*metabolism MH - Cerebral Infarction MH - Down-Regulation MH - Drugs, Chinese Herbal/*therapeutic use MH - Interleukin-1beta MH - Interleukin-6 MH - Rats MH - Rats, Sprague-Dawley MH - Reperfusion Injury MH - Tablets MH - Toll-Like Receptor 2/*metabolism MH - Up-Regulation MH - p38 Mitogen-Activated Protein Kinases/*metabolism EDAT- 2015/08/06 06:00 MHDA- 2016/04/27 06:00 CRDT- 2015/08/06 06:00 PHST- 2015/08/06 06:00 [entrez] PHST- 2015/08/06 06:00 [pubmed] PHST- 2016/04/27 06:00 [medline] PST - ppublish SO - Zhongguo Zhong Xi Yi Jie He Za Zhi. 2015 Jun;35(6):712-6.